Don't miss a thing.
Subscribe to email for more resources.
The U.S.
Food and Drug Administration (FDA) has approved the drug Benlysta ( belimumab ) for the treatment of lupus nephritis (LN) in children and teens aged 5 to 17 who are receiving standard therapy.
Benlysta is a human monoclonal antibody that was first approved in 2011 as a treatment for adults with lupus, and was approved to treat lupus nephritis in adults in 2020 .
It is now the first and only approved biologic for both lupus and LN for adults and children.
This is the first FDA-approved treatment for pediatric LN.
Before this approval treatment options were limited to less tolerable medications including corticosteroids , antimalarials, and immunosuppressants (a type of drug that lowers the body’s ability to mount an immune response)).
These medicines were developed for other diseases, and often have serious and debilitating side effects in children and teens.
As a result, many struggled to follow their medication treatment plans.
LN is a common and serious complication of lupus that causes kidney inflammation and can lead to end-stage kidney disease.
The approval represents a major advancement for treating LN earlier in life and helping prevent damage at a young age.
Between 15 and 20 percent of all cases of lupus develop during childhood.
The symptoms of childhood lupus are more intense, and the long-term organ damage can be more severe.
Recognizing these challenges, the Lupus Foundation of America established the first and only national childhood lupus research program, The Michael Jon Barlin Pediatric Lupus Research Program .
The program supports discoveries in childhood lupus research and has funded important studies to develop better ways to treat and manage lupus in children and teens.
Continue to follow the Lupus Foundation of America for breaking lupus treatment news.
Learn more about caring for children and teens with lupus .
Read the announcement Interested in getting research like this straight to your inbox?
Subscribe to our bimonthly Inside Lupus Research email for all the latest.
There are multiple chapters near you.
Select your preferred chapter.
Supporting lupus patients and advocates in Arizona.
Serving the District of Columbia, Maryland, and Northern Virginia.
Serving southern Illinois up to and including Springfield, eastern Kansas, and Missouri Serving northern and central Illinois Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas Serving all northern counties in New Jersey, south through Mercer and Ocean counties Supporting lupus patients and advocates in the Northeast.
Serving Pennsylvania, all southern counties in New Jersey up through Burlington County, and Delaware Serving Houston, Beaumont, Corpus Christi, Harlingen and surrounding areas in Texas There are multiple walks near you. source